On February 26, 2026, Quotient Sciences, a leading CRDMO, and global biopharmaceutical company Ipsen announced the extension of their commercial manufacturing agreement. The partnership focuses on the continued production of Sohonos (Palovarotene), a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare condition affecting fewer than 1,000 individuals globally.
Sohonos involves highly potent active pharmaceutical ingredients (HPAPI), necessitating specialized containment technologies to protect operators and facilities. To support this, Ipsen has invested in advanced equipment at Quotient Sciences’ Pennsylvania site, including a Pneumatic Closed Transfer System and a Flexible Dispensing Isolator. These upgrades enable the safe handling of potent molecules with occupational exposure limits (OELs) at or below while ensuring seamless integration with existing production lines.
This expansion secures a reliable commercial supply of critical FOP therapy and broadens Quotient Sciences’ capabilities to manage multiple highly potent compounds at scale. The collaboration underscores a shared commitment to addressing critical needs in the ultra-rare disease sector through flexible and high-quality manufacturing solutions.